Teladoc Q2 revenue $631.9M (-2% YoY); adjusted EBITDA $69.3M (-23%); retires $550.6M convertible notes

Teladoc Health, Inc.

2025-Q2 EPS reported -$0.72 revenue$1,261,269,000

Net loss of $32.7M ($0.19 per share), improved from $837.7M loss in Q2 2024 which included $790M goodwill impairment.
Integrated Care segment revenue $391.5M (+4% YoY); BetterHelp revenue $240.4M (-9% YoY).
Paid $550.6M cash to retire convertible notes; entered a five-year $300M secured revolving credit facility on July 17.
Full-year 2025 revenue guidance $2,501–$2,548M; adjusted EBITDA $263–$294M; Q3 revenue guidance $614–$636M.
Free cash flow $61.2M in Q2 vs. $60.9M in Q2 2024; Capex $30.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.